Oaktree Acquisition Corp. III Life Sciences Segments Disclosure
For the Year Ended December 31, 2025 |
For the Period From June 28, 2024 (inception) through December 31, 2024 |
|||||||
General and administrative expenses |
$ | 1,195,687 | $ | 351,806 | ||||
Interest earned on cash held in Trust Account |
$ | 8,484,511 | $ | 1,588,732 | ||||
December 31, 2025 |
December 31, 2024 |
|||||||
Cash held in Trust Account |
$ | 201,563,532 | $ | 193,579,022 | ||||
Want the next Oaktree Acquisition Corp. III Life Sciences segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Oaktree Acquisition Corp. III Life Sciences's next filing hits EDGAR. No credit card, your email never gets sold.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.